2023 J. Allyn Taylor International Prize in Medicine Symposium
Celebrating outstanding innovations and research in biotherapeutics – don't miss this ground breaking research event of the year!
Join us on Wednesday, November 15, 2023 for a half-day Symposium taking a 360-degree view of biotherapeutics. Examining the science, the politics and the economics on what is being called the next generation of therapeutic tools.
Featuring a keynote lecture by the 2023 J. Allyn Taylor International Prize in Medicine recipient, Nabil G. Seidah, PhD.
Registration table opens - Coffee and refreshments served
Opening and welcome remarks
Presented by: Amandalina Letterio, CTV London
Nabil G. Seidah, PhD
Director, Biochemical Neuroendocrinology Research Unit, Montreal Clinical Research Institute
Professor, Department of Medicine, University of Montreal
The long and winding road leading to the discovery of the proprotein convertases and their translational applications in health and disease
The discovery of the protein convertases and the deciphering of their biological functions opened the door to unsuspected powerful diagnostics and treatments of major human pathologies including cardiovascular diseases, viral infections and cancer/metastasis. The amazing applications of PCSK9 inhibitors in the effective treatment of hypercholesterolemia and beyond is but one example of the power of the scientific method when ignited and driven by intuitive insights and persistent efforts can lead to the development of innovative therapies for the good of mankind.
Lauren Cipriano, PhD
Associate Professor, Management Science, Ivey Business School, Western University
Associate Professor, Epidemiology and Biostatistics, Schulich Medicine & Dentistry, Western University
Health economics and the opportunity cost of extraordinarily expensive biotherapeutics
Canadians pay the third highest patented drug prices in the world with the median treatment cost for the 20 top-selling patented drugs, accounting for almost 40 per cent of total sales, increasing from $730 to $42,600 over the past decade. Routinely, health economic evaluations identify that greater than 90 per cent discounts would be required for new drugs to be considered cost effective; an Ontario Auditor General's report found the average discount achieved through negotiation is approximately 30 per cent. The opportunity cost we pay for public access to extraordinarily expensive drugs is longer surgical wait times and other procedures, reduced access to homecare, and under-investment in health care infrastructure to support an aging population.
Dr. Rob Hegele
Scientist, Molecular Medicine, Robarts Research Institute
Distinguished University Professor, Departments of Medicine and Biochemistry, Schulich Medicine & Dentistry, Western University
New and improved! Biological therapies for dyslipidemias
What do new therapies for patients with dyslipidemias look like? With advancing technologies and approved modalities, including recently approved injectable monoclonal antibodies and RNA interference drugs, more biological therapies are available now for patients with even more under development. What do we prescribe and where do we go from here?
Dr. Kun Ping Lu
Professor, Department of Biochemistry, Schulich Medicine & Dentistry, Western University
Navigating the frontiers of biotherapeutic discovery: Unraveling the science, challenges, and promise
Discover the early stages of biotherapeutic development, unravel the science of targeting specific processes, and explore limitless potential of biotherapeutic discovery. Delve into the essence of biotherapeutic research, leveraging existing knowledge to craft groundbreaking therapies. Critically, the novel uses of Monoclonal antibodies (MABs) - like Cis p-tau - for diagnostic uses and treatment of diseases like Alzheimer's, vascular dementia, TBI and stroke.
Jennifer Quizi, PhD
Investigator and Director, Biotherapeutics Manufacturing Centre, Virus Manufacturing Facility (BMC-VMF)
The Ottawa Hospital Research Institute
Lost in translation: The critical role of biomanufacturing in pre-clinical to clinical translation of novel biotherapeutics
Biologic therapies, also known as biotherapeutics, are treating and curing previously untreatable and uncurable diseases like spinal muscular atrophy (Zolgensma), hemophilia B (Hemgenix) and even specific types of cancer (e.g. Kymriah; Yescarta; Tecartus). However, the cost to translate these biotherapeutic innovations, from bench discovery to the patient’s bedside, let alone provide sustainable and equitable access to those that show benefit, is highly limited by the cost associated with their manufacture. As ‘living drugs’, biotherapeutics are very complex, and therefore costly to make. They require specialized facilities and equipment, with long process durations, expensive raw materials and most importantly, a team of highly qualified personnel (HQP). In fact, biologics are currently the most expensive class of treatment with some costing more than $3M per dose!
Once again, we've opened the doors to the community all are welcome to attend this complimentary event, but registration is required as seats are limited.
Please note that visitor parking is available at multiple visitor parking lots on Western's Campus.
Complement your Symposium experience by joining the Celebrating Science and Discovery Dinner the evening of November 15.
Proudly supported by the C.H. Stiller Memorial Foundation and the family of J. Allyn Taylor.
Thank you to our community sponsors: